CN112869150A - Astaxanthin composition, and preparation method, preparation and application thereof - Google Patents
Astaxanthin composition, and preparation method, preparation and application thereof Download PDFInfo
- Publication number
- CN112869150A CN112869150A CN202110350428.9A CN202110350428A CN112869150A CN 112869150 A CN112869150 A CN 112869150A CN 202110350428 A CN202110350428 A CN 202110350428A CN 112869150 A CN112869150 A CN 112869150A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- skin
- composition
- astaxanthin composition
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 171
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 171
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 170
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 168
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 162
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000036548 skin texture Effects 0.000 claims abstract description 10
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 8
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 30
- 102000008186 Collagen Human genes 0.000 claims description 22
- 108010035532 Collagen Proteins 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- 102000016942 Elastin Human genes 0.000 claims description 18
- 108010014258 Elastin Proteins 0.000 claims description 18
- 229920002549 elastin Polymers 0.000 claims description 18
- 241000251468 Actinopterygii Species 0.000 claims description 17
- 241000269851 Sarda sarda Species 0.000 claims description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 15
- 229930003268 Vitamin C Natural products 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- -1 astaxanthin diester Chemical class 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 206010040829 Skin discolouration Diseases 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 22
- 230000032683 aging Effects 0.000 abstract description 13
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 238000005282 brightening Methods 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 89
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- 239000011148 porous material Substances 0.000 description 13
- 230000001815 facial effect Effects 0.000 description 11
- 230000002354 daily effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000036559 skin health Effects 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 230000037075 skin appearance Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000003010 ionic group Chemical group 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PSQYTAPXSHCGMF-BQYQJAHWSA-N beta-ionone group Chemical group CC1=C(C(CCC1)(C)C)/C=C/C(C)=O PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001749 carotenones Chemical class 0.000 description 1
- 235000005472 carotenones Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 229940049494 hyaluronic acid 20 mg Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an astaxanthin composition, and a preparation method, a preparation and an application thereof. The astaxanthin composition is applied to preparing products for moisturizing skin, resisting wrinkles, tightening skin, brightening skin, resisting spots, improving skin textures, improving rough skin caused by long-wave ultraviolet rays in UVB-UVA, relieving skin inflammation, resisting oxidation and beautifying and resisting aging on skin.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an astaxanthin composition, and a preparation method, a preparation and application thereof.
Background
The skin is mainly composed of three parts, namely an epidermal layer, a dermal layer and a subcutaneous tissue, and is the largest organ of a human body. The generation of the aging is the result of the combined action of endogenous aging and exogenous environmental factors, and the endogenous aging, namely the aging caused by the irresistible physiological evolution factors such as heredity, endocrine and the like of the human body, is the root of the aging; the exogenous environmental factors are aging caused by the influence of human body by light radiation, season change, environmental pollution, bad living habits, living pressure, diseases and the like.
The main pathological changes of skin aging include the reduction of the thickness of the skin, the reduction of the collagen content of the skin, the elasticity reduction, the excessive deposition of oxidation products in the skin, the relaxation and sagging of the soft tissue structure of the skin and the deep layer of the skin, and the like, and the external manifestations can be summarized as dryness, wrinkles, color spots and thinning.
The physiological function states of the skin layers are closely related to the formation of skin aging, and can be summarized as follows: (1) epidermal stratum corneum alteration: the stratum corneum is the outermost layer of the skin and has the functions of protection, moisture preservation, sun protection, absorption and the like, and the stratum corneum is changed and is easily affected by the adverse effect of the external environment, and the skin is affected by the change, so that various problems of the skin, such as pigmentation, telangiectasia of the skin and the like, are caused by invasion of the skin. (2) Modification of base film: the basement membrane, which is located at the interface between the dermis and epidermis layers of the skin, is responsible for the exchange of substances between the two layers, which gradually breaks and flattens as the skin ages, thus leading to a consequent thinning of the skin and a gradual obstacle to the exchange of substances between the two layers of tissue. Research shows that substances capable of promoting the repair of basement membranes can effectively delay the aging of skin. (3) Dermal architecture modification: the reduction of collagen fibers (collagenous fibers), reticular fibers (fibrous fibers), elastic fibers (elastic fibers), etc. in the dermal structure can cause thinning, laxity, dryness and dullness of the skin. The elasticity of skin is mainly related to elastic fibers, when the elastic fiber net of the dermal papilla of the skin is gradually broken and disappears, the content of elastin is gradually reduced, the aging speed of the skin starts to be accelerated, and the relaxation phenomenon of the skin starts to be generated, such as canthus droop, generation of a justice and the like. (4) Sebaceous gland atrophy: with the increasing age, sebaceous glands further atrophy, so that the subcutaneous fat layer becomes thinner, the water content of the skin continuously decreases, and aging phenomena such as roughness, dryness and the like occur. It is necessary to develop a product capable of solving the above problems.
Disclosure of Invention
The first object of the present invention is to provide an astaxanthin composition; the second purpose is to provide a preparation method of the astaxanthin composition; the third purpose is to provide a preparation of the astaxanthin composition; the fourth purpose is to provide the application of the astaxanthin composition.
The first object of the present invention is achieved by an astaxanthin composition comprising astaxanthin, bonito elastin peptide, fish collagen peptide, natural vitamin C and hyaluronic acid.
The second purpose of the invention is realized by uniformly mixing the raw materials in the formula ratio to obtain the target astaxanthin composition.
The third purpose of the invention is realized by adding auxiliary materials into the astaxanthin composition to prepare tablets, oral liquid, powder, granules, capsules, powder or pills.
The fourth object of the present invention is achieved by the use of the astaxanthin composition for the preparation of a product for moisturizing the skin, anti-wrinkling, firming, lightening, anti-spotting, improving the texture of the skin, improving the roughness of the skin caused by the ultraviolet radiation of the long wave of the UVB-UVA, reducing the inflammation of the skin, anti-oxidant, cosmetic and anti-ageing of the skin.
Astaxanthin (Astaxanthin), also known as Astaxanthin and lobster shell pigment, is widely distributed as a non-vitamin a-protolipid-soluble ketocarotenoid in marine animals and plants, microalgae and yeasts. The chemical name of astaxanthin is 3,3 ' -dihydroxy-4, 4 ' -diketone-beta, beta ' -carotene, and the molecular formula is C40H52O4The chemical structure is a six-membered ring structure formed by connecting 4 isoprene units in a conjugated double bond mode and two isoprene units at two ends. The haematococcus pluvialis contains about 5%, 70% and 25% of free astaxanthin, astaxanthin monoester and astaxanthin diester respectively, and the structures of the free astaxanthin, astaxanthin monoester and astaxanthin diester are shown as follows:
the free astaxanthin exists mostly as All-trans astaxanthin (All-trans-astaxanthin), the 3S, 3 'S astaxanthin has better physiological activity compared with astaxanthin of other structural types, and the structure of All-trans-3S, 3' S astaxanthin (All-trans-levo-astaxanthin) is shown as follows:
the special beta-ionone ring and long-chain conjugated olefin structure in the molecular structure of astaxanthin endows the astaxanthin with the function of effectively quenching active oxygen, is the strongest natural antioxidant in nature so far, has the capacity of scavenging free radicals more than 500 times of that of vitamin E and other carotenoids (lutein, lycopene and beta-carotenoid), and is the only carotenoid which is found to penetrate the Blood-Brain (Blood-Brain) and Blood-Retina (Blood-Retina) barriers, and a large number of animal experiments show that: astaxanthin has antitumor, antiinflammatory, antidiabetic, oxidative damage reducing, immunity enhancing, motor function improving, and cardiovascular and cerebrovascular diseases preventing effects.
The invention relates to AstaMAZ natural astaxanthin 20-500mg (resisting wrinkles, increasing skin elasticity, reducing free ionic groups, reducing skin pigmentation and enhancing skin texture), bonito elastin peptide 500mg, fish collagen peptide 100mg (the effects of the two protein peptides are reducing wrinkles, age spots and pores, improving skin texture and smoothness, improving overall skin health), natural vitamin C20-400 mg (resisting oxidation, reducing free ionic groups and improving astaxanthin efficacy), hyaluronic acid 10-30mg (skin moisturizing and resisting oxidation efficacy), 100mL of drinkable purified water is added, and the astaxanthin composition oral liquid can be prepared by ultrasonic mixing. Generally speaking, the components have the effect of mutual synergy after being combined.
Drawings
FIG. 1 is a schematic diagram showing the effect of astaxanthin composition (PA) according to the invention on facial wrinkles;
wherein A is the long and narrow shape of wrinkles in the experimental group and the comparison after VISIA tracking identification;
b is wrinkle difference comparison of astaxanthin composition (PA) and control group at 0, 4 and 8 weeks;
FIG. 2 is a schematic representation of the effect of astaxanthin composition (PA) of the present invention on skin appearance;
wherein a is a graphical representation of a significant reduction in texture change at 4 weeks and 8 weeks for the astaxanthin composition (PA) group compared to 0 weeks;
b is the significant difference in skin texture change (p < 0.05) between the astaxanthin composition (PA) group and the control group at weeks 4 and 8;
FIG. 3 is a schematic representation of the effect of astaxanthin composition (PA) of the present invention on age spots;
fig. 4 is a schematic diagram showing the effect of the astaxanthin composition (PA) according to the invention on pores;
fig. 5 is a schematic representation of the overall improvement in skin health of the astaxanthin composition (PA) of the present invention;
fig. 6 is a schematic representation of the effect of the astaxanthin composition (PA) of the present invention on skin damage induced by long wavelength ultraviolet (UVB-UVA) in the skin;
fig. 7 is a schematic diagram of the astaxanthin composition (PA) of the present invention for reducing water loss from the skin in the medium wavelength uv radiation zone;
fig. 8 is a graph showing the change in VAS score for the astaxanthin composition (PA) of the present invention to improve rough skin and texture;
FIG. 9 is a graph showing that the expression levels of IL-1a, THF-alpha, IL-6, and IFN- ү in the stratum corneum of the skin were significantly decreased after 9 weeks of administration of the astaxanthin composition (PA) according to the present invention;
fig. 10 is a schematic diagram showing that the expression level of MDA in the stratum corneum of the skin is significantly decreased and the SOD level is significantly increased after the astaxanthin composition (PA) of the present invention is taken for 9 weeks.
Detailed Description
The present invention is further illustrated by the following examples and the accompanying drawings, but the present invention is not limited thereto in any way, and any modifications or alterations based on the teaching of the present invention are within the scope of the present invention.
The astaxanthin composition comprises astaxanthin, bonito elastin peptide, fish collagen peptide, natural vitamin C and hyaluronic acid.
The astaxanthin composition comprises 20-500mg of astaxanthin, 500-1000mg of bonito elastin peptide, 100-500mg of fish collagen peptide, 20-400mg of natural vitamin C and 10-30mg of hyaluronic acid.
The astaxanthin is natural astaxanthin.
The astaxanthin is L-astaxanthin.
The astaxanthin comprises free astaxanthin, astaxanthin monoester and astaxanthin diester.
The mass percentages of the free astaxanthin, the astaxanthin monoester and the astaxanthin diester are respectively 5-20%, 60-70% and 20-25%.
The preparation method of the astaxanthin composition comprises the step of uniformly mixing the raw materials in the formula ratio to obtain the target astaxanthin composition.
The preparation of the astaxanthin composition is prepared by adding auxiliary materials into the astaxanthin composition to prepare tablets, oral liquid, powder, granules, capsules, powder or pills.
The application of the astaxanthin composition is the application of the astaxanthin composition in preparing products for moisturizing, wrinkle resisting, skin firming, skin brightening, anti-spot, skin texture improving, rough skin caused by long-wave ultraviolet rays in UVB-UVA, skin inflammation relieving, oxidation resisting, skin beautifying and aging resisting.
The invention is further illustrated by the following specific examples:
example 1
Weighing 20mg of AstaMAZ natural astaxanthin, 500mg of bonito elastin peptide, 100mg of fish collagen peptide, 20mg of natural vitamin C and 10mg of hyaluronic acid, and uniformly mixing to obtain the target astaxanthin composition.
Example 2
500mg of AstaMAZ natural astaxanthin, 1000mg of bonito elastin peptide, 500mg of fish collagen peptide, 400mg of natural vitamin C and 30mg of hyaluronic acid are weighed and mixed uniformly to obtain the target astaxanthin composition.
Example 3
Weighing 300mg of AstaMAZ natural astaxanthin, 800mg of bonito elastin peptide, 300mg of fish collagen peptide, 300mg of natural vitamin C and 20mg of hyaluronic acid, and uniformly mixing to obtain the target astaxanthin composition.
Example 4
100mg of AstaMAZ natural astaxanthin, 900mg of bonito elastin peptide, 200mg of fish collagen peptide, 100mg of natural vitamin C and 15mg of hyaluronic acid are weighed and uniformly mixed to obtain the target astaxanthin composition.
Example 5
50mg of AstaMAZ natural astaxanthin, 800mg of bonito elastin peptide, 150mg of fish collagen peptide, 30mg of natural vitamin C and 25mg of hyaluronic acid are weighed and uniformly mixed to obtain the target astaxanthin composition.
Example 6
200mg of AstaMAZ natural astaxanthin, 700mg of bonito elastin peptide, 400mg of fish collagen peptide, 80mg of natural vitamin C and 18mg of hyaluronic acid are weighed and uniformly mixed to obtain the target astaxanthin composition.
Example 7
Weighing AstaMAZ natural astaxanthin 400mg, bonito elastin peptide 500mg, fish collagen peptide 100mg, natural vitamin C200 mg and hyaluronic acid 20mg, and uniformly mixing to obtain the target astaxanthin composition.
Example 8
350mg of AstaMAZ natural astaxanthin, 780mg of bonito elastin peptide, 320mg of fish collagen peptide, 220mg of natural vitamin C and 19mg of hyaluronic acid are weighed and mixed uniformly to obtain the target astaxanthin composition.
Example 9
Weighing 20mg of AstaMAZ natural astaxanthin, 1000mg of bonito elastin peptide, 500mg of fish collagen peptide, 20mg of natural vitamin C and 30mg of hyaluronic acid, and uniformly mixing to obtain the target astaxanthin composition.
Example 10
Weighing AstaMAZ natural astaxanthin 90mg, bonito elastin peptide 700mg, fish collagen peptide 300mg, natural vitamin C400 mg and hyaluronic acid 22mg, and uniformly mixing to obtain the target astaxanthin composition.
Example 11
500mg of AstaMAZ natural astaxanthin, 500mg of bonito elastin peptide, 100mg of fish collagen peptide, 180mg of natural vitamin C and 16mg of hyaluronic acid are weighed and uniformly mixed to obtain the target astaxanthin composition.
Example 12
The astaxanthin composition prepared in example 9 was added with pharmaceutically or dietetically acceptable excipients to prepare tablets.
Example 13
Adding 100-500 ml of purified drinking water into the astaxanthin composition prepared in example 7, and carrying out ultrasonic mixing to obtain the oral liquid.
Example 14
The astaxanthin composition prepared in example 3 is added with pharmaceutically or dietetically acceptable auxiliary materials to prepare powder.
Example 15
The astaxanthin composition prepared in example 11 was added with pharmaceutically or dietetically acceptable excipients to prepare granules.
Example 16
The astaxanthin composition prepared in example 2 was added with pharmaceutically or dietetically acceptable excipients to prepare capsules.
Example 17
The astaxanthin composition prepared in example 5 was added with pharmaceutically or dietetically acceptable excipients to prepare a powder.
Example 18
Therefore, the astaxanthin composition prepared in example 8 is added with pharmaceutically or dietetically acceptable auxiliary materials to prepare pills.
Example 19
The astaxanthin composition (PA) prepared in example 7 was tested as follows:
1. example 7 double-blind experiment of the astaxanthin composition (PA) prepared in the example for the improvement of skin moisture
1.1 subjects and groups
The experimental subjects are 120 volunteer subjects, the skin moisture is less than or equal to 14 percent, and the experimental subjects are divided into a suction group: 60, male 30, female 30, age: 46.23 + -4.22 years old; control group: 60, male 30, female 30, age: 46.37 + -4.41 years old
1.2 test period: 30 days
1.3 Experimental methods: the test was conducted by a double-blind method, wherein the astaxanthin composition (PA) sample prepared in example 7 or a placebo (normal drinking water) was administered to the test group and the control group, respectively, 1.5g of PA sample per time and 1 time per day, and the other oral and topical skin moisture-retaining agents were stopped during the test period. The original diet habit was not changed during the test period, and the diet was normal. The forehead intereyebrow skin moisture was measured 1 time each at the beginning and end of the feeding trial. The test is carried out in an inspection room with spacious, good ventilation condition and stable space environment such as temperature, humidity and the like; cleaning the tested part with clean cotton ball dipped with distilled water under quiet state, wiping to dry, performing water content test for 12 min, and performing the test before and after eating on the same instrument by the same person.
1.4 test instruments: skin moisture tester Corneometer CM 825 (Courage + Khazaka, germany);
1.5 purpose of experiment: detection of the improvement Effect of PA on facial skin moisture
Note: p <0.05 vs self control and # P <0.05 vs interclass control.
Conclusion 1: after daily intake of the astaxanthin composition (PA) prepared in example 7, facial skin moisture was significantly improved after 30 days.
2. Example 7 Effect of astaxanthin composition (PA) prepared in the preparation of anti-aging agent for facial skin
2.1 subjects and groups
Subjects were 100 healthy women between the ages of 38-70, test group (PA): 50 names; control group (control): 50 name of
2.2 test period: 4-8 weeks
2.3 Experimental methods: the test was conducted by a double-blind method, wherein the astaxanthin composition (PA) prepared in example 7 or a placebo (normal drinking water) was administered to the test group and the control group, respectively, 1.5g of PA drink was administered 1 time per day, and the two groups of subjects prohibited from using cosmetics which are not used at ordinary times, medicines which are not used at ordinary times, traditional Chinese medicines, health foods which are taken at ordinary times, skin care in beauty salons, Spa and the like, intake of excessive alcohol, excessive sun exposure, excessive exercise, intake of pungent substances such as spicy and hot foods, bathing before measurement, administration of beverages with a large vitamin C content, and face washing on the same day as that of ordinary measurement.
2.4 test methods: VISIA technology for analyzing digital images of facial skin is used for determining changes of skin wrinkles, lines, age spots, pores and the like before and after treatment.
1) Effect of astaxanthin composition (PA) prepared in example 7 on facial wrinkles, see fig. 1, a in fig. 1) long narrow shape of wrinkles in right panel experimental group and comparison after VISIA (left) trace recognition;
as can be seen, after 4 weeks, the number of wrinkles in the astaxanthin composition oral liquid group (PA) was all reduced compared to before treatment, and after 8 weeks, the wrinkles in the astaxanthin composition oral liquid group (PA) were significantly reduced; b) The wrinkle difference of the astaxanthin composition oral liquid group (PA) and the control group in 0, 4 and 8 weeks is compared, the wrinkle amount of the four-week group is different, and the wrinkle amount of the astaxanthin composition oral liquid group (PA) in the eighth week is obviously reduced and is obviously different from that of the control group (p is less than 0.05).
Conclusion 2: daily intake of the astaxanthin composition (PA) prepared in example 7 for 8 weeks significantly reduced facial wrinkles by about 10%, making the appearance more youthful.
2) Effect of astaxanthin composition (PA) prepared in example 7 on skin appearance
VISIA texture analysis measures skin color and smoothness by identifying color gradation from surrounding skin tone, and changes in the peaks and valleys of the skin surface, the texture of the skin surface, resulting in uneven skin, see fig. 2, a) in fig. 2, the astaxanthin composition (PA) group prepared in example 7 had significantly reduced texture changes at 4 and 8 weeks compared to 0 week; B) the astaxanthin composition (PA) prepared in example 7 showed significant differences in skin texture changes from the control group at weeks 4 and 8 (p < 0.05).
Conclusion 3: daily intake of the astaxanthin composition (PA) prepared in example 7 significantly improved the overall appearance of the facial skin, with a more uniform appearance at both 4 and 8 weeks (approximately 12% difference in skin texture compared to the control).
3) Effect of astaxanthin composition (PA) prepared in example 7 on age spots
Changes in age spots-VISIA spot analysis can detect age spots such as brown and red skin lesions including pigmentation, chloasma, acne spots, vascular lesions and small freckles. The brown spots were caused by an excessive amount of melanin produced by melanocytes in the bottom layer of the epidermis, resulting in uneven skin appearance, see fig. 3, a-B in fig. 3) in the control group, there was a tendency for the number of senile plaques to increase (+ 4%). In contrast, the number of age spots (brown and red skin lesions including pigmentation, chloasma, acne, vascular lesions and small freckles) of the astaxanthin composition (PA) prepared in example 7 was significantly reduced at 4 weeks compared to before treatment (0 weeks) (fig. 3, p < 0.05).
Conclusion 4: daily ingestion of the astaxanthin composition (PA) prepared in example 7 significantly reduced age spots and improved the overall appearance of the facial skin, thereby making the appearance brighter.
4) Effect of astaxanthin composition (PA) prepared in example 7 on pores
Changes in pores-VISIA pore analysis measures the openings at the skin surface. Pores are distinguished from spots by their darker color, smaller size, and rounded shape. Pores are the ligaments connecting the sebaceous glands with the hair follicles and the skin surface, and are critical to the function of the skin. Facial pore enlargement is caused by a variety of factors, including sun exposure, aging, accumulated oil, dead skin cells, and genes. All of these have negative effects on collagen and elastin-these are the two major components of the skin's structural support system. The pores are unsupported due to the loss of collagen and appear larger, see fig. 4, a-B in fig. 4) the astaxanthin composition (PA) prepared in example 7 showed a significant reduction in the number of pores at 8 weeks compared to 0 weeks (p < 0.05), compared to no significant change in the control group.
Conclusion 5: daily intake of the astaxanthin composition (PA) prepared in example 7 significantly reduced the number of facial pores, making it less noticeable.
5) Example 7 the overall improvement in skin health of the astaxanthin composition (PA) prepared, see fig. 5, a-B in fig. 5) a comprehensive skin health assessment-in addition to daily diary writes, the participants were asked to provide a self assessment of a specific criteria at the end of the study. The number of responses "improved and better" was significantly greater (30%) at weeks 4 and 8, and the proportion of astaxanthin composition (PA) prepared in example 7 was 70% compared to the control group.
Conclusion 6: the astaxanthin composition (PA) prepared in example 7 was orally administered daily for 4 weeks and 8 weeks to improve the general skin condition of the face and to affect fine lines, wrinkles, age spots and pore size. In addition, pigmentation, texture, tone and smoothness were all significantly improved, making people look younger.
6) Example 7 Effect of the astaxanthin composition (PA) prepared in the example on skin Damage induced by Medium wavelength ultraviolet rays (UVB-UVA)
Experiment design: participants were between 35 and 65 years of age; 30 women and 30 men, which are divided into an astaxanthin composition oral liquid PA group (30 people, half of men and women), wherein each person takes one astaxanthin composition oral liquid PA every day, a placebo group (30 people, half of men and women) takes a placebo (control), the test is a random double-blind test and lasts for 9 weeks, and the middle-wavelength ultraviolet (UVB-UVA) radiation area is the back skin; after UV irradiation, skin moisture content and TEWL, anti-inflammatory and antioxidant effects were measured.
Representative imaging of irradiated areas of control (left) and astaxanthin composition (PA) prepared in example 7 (right) before and after a) supplementation in fig. 6; B) the MED of the control group (black) and the astaxanthin composition (PA) prepared in example 7 was changed from the baseline. Mann-Whitney U-testp < 0.05.
The astaxanthin composition (PA) prepared in example 7 of fig. 7 reduced the water loss of the skin in the middle wavelength ultraviolet (UVB-UVA) radiation zone. Change in baseline humidity in the irradiated area 7 days after irradiation. The moisture level of the irradiated area was corrected with the moisture level of the non-irradiated area, p < 0.05.
Fig. 8, a-B) the VAS score changes for rough skin "and" texture "improved by the astaxanthin composition (PA) prepared in example 7, (a) texture" (B) baseline of non-irradiated area of control group (control) and astaxanthin composition oral liquid (PA) group. Positive and negative values indicate improvement and deterioration of the skin, T-test, p <0.05, p < 0.01, respectively.
Fig. 9, a-D) shows that the expression levels of IL-1a, THF- α, IL-6, and IFN- ү in the stratum corneum of the skin were significantly decreased after 9 weeks of administration of the astaxanthin composition (PA) prepared in example 7, and there was no significant difference (p > 0.05) compared to the control group (control), indicating that the astaxanthin composition (PA) prepared in example 7 can prevent the occurrence of skin inflammation caused by irradiation of medium-long wavelength ultraviolet (UVB-UVA).
3. The antioxidant stress effect of the astaxanthin composition (PA) prepared in example 7 is shown in fig. 10, wherein a-B) in fig. 10, after the astaxanthin composition (PA) prepared in example 7 is taken for 9 weeks, the MDA expression level of the stratum corneum of the skin is significantly reduced, the SOD level is significantly increased, and there is no significant difference (p > 0.05) compared with the control group (control), which indicates that the astaxanthin composition (PA) prepared in example 7 can prevent the skin oxidative stress caused by the irradiation of medium-long wavelength ultraviolet rays (UVB-UVA), and has an anti-aging effect.
Conclusion 7: the astaxanthin composition (PA) prepared in example 7 can increase the tolerance of skin to long wavelength ultraviolet rays (UVB-UVA) and reduce the decrease in skin moisture of healthy people caused by the medium wavelength ultraviolet rays (UVB-UVA), can improve the roughness and texture damage of skin caused by the irradiation of the medium wavelength ultraviolet rays (UVB-UVA), reduce skin inflammation, is antioxidant, and has a repairing effect of preventing the damage of skin caused by the medium wavelength ultraviolet rays (UVB-UVA) and after the damage.
And (4) conclusion: the moisture, wrinkles and brown spots of the skin are several important indexes of skin aging, as the skin ages, fibroblasts in the dermis layer gradually lose vitality, the solubility of collagen is reduced, the locking function of the skin on the moisture is reduced, and the skin aging process can be slowed down through external water supplement. Wrinkles on the surface of the skin mean wrinkles formed by the contraction of the skin surface and are the first signs of skin aging. Ultraviolet light is liable to cause photoaging of the skin, forming brown spots. The astaxanthin composition (PA) prepared in example 7 has moisturizing, anti-wrinkle, pore-shrinking (tightening), skin-lightening, pigment and age pigment reduction (anti-spot), skin smoothness increasing (skin texture improvement) effects on the skin in daily use, and is also effective in improving rough skin caused by ultraviolet rays of medium and long wavelength of UVB-UVA, reducing skin inflammation, resisting oxidation, and having cosmetic and anti-aging effects on the skin. In the formulation of the astaxanthin composition (PA) prepared in example 7, the AstaMAZ natural astaxanthin (derived from Haematococcus pluvialis) used contained free astaxanthin, monoester-type astaxanthin and diester-type astaxanthin, which are considered to be the active ingredients of the product at the same time, and all the three ingredients and their metabolites in vivo have the skin beautifying and anti-aging effects mentioned above.
Example 20
The astaxanthin compositions prepared in examples 1, 2, 3, 4, 5, 6, 8, 9, 10 and 11 were tested, and the results of the same method as example 19 show that the astaxanthin composition of the present invention has the effects of moisturizing skin, removing wrinkles, shrinking pores (tightening skin), improving skin luster (brightening skin), reducing pigment and senile plaque (anti-spot), and increasing skin smoothness (improving skin texture) in daily use, and is also effective in improving rough skin caused by UVB-UVA medium-long wave ultraviolet rays, reducing skin inflammation, resisting oxidation, and achieving the effects of beautifying and resisting aging on the skin.
Claims (10)
1. An astaxanthin composition, which is characterized by comprising astaxanthin, bonito elastin peptide, fish collagen peptide, natural vitamin C and hyaluronic acid.
2. The astaxanthin composition according to claim 1, wherein the astaxanthin composition comprises 20 to 500mg of astaxanthin, 500 to 1000mg of bonito elastin peptide, 100 to 500mg of fish collagen peptide, 20 to 400mg of natural vitamin C, and 10 to 30mg of hyaluronic acid.
3. An astaxanthin composition according to claim 1 or 2, wherein said astaxanthin is natural astaxanthin.
4. An astaxanthin composition according to claim 1 or 2, wherein said astaxanthin is a levorotatory astaxanthin.
5. An astaxanthin composition according to claim 1 or 2, wherein said astaxanthin comprises free astaxanthin, astaxanthin monoester and astaxanthin diester.
6. The astaxanthin composition according to claim 5, wherein the astaxanthin in free form, the astaxanthin monoester and the astaxanthin diester are present in an amount of 5-20%, 60-70% and 20-25% by weight, respectively.
7. The astaxanthin composition according to claim 6, wherein the free astaxanthin is all-trans L-astaxanthin.
8. A method for preparing an astaxanthin composition as claimed in any one of claims 1 to 7, wherein the astaxanthin composition is obtained by mixing the raw materials in the formulation ratio.
9. An astaxanthin composition preparation according to any one of claims 1 to 7, wherein the astaxanthin composition is prepared into tablets, oral liquids, powders, granules, capsules, powders or pills by adding adjuvants.
10. Use of an astaxanthin composition according to claims 1-7 for the preparation of a skin moisturizing, anti-wrinkle, skin firming, skin lightening, anti-spotting, skin texture improvement, skin roughness improvement due to uv light of the medium and long wavelength of UVB-UVA, skin inflammation reduction, anti-oxidant, skin cosmetic and anti-aging product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110350428.9A CN112869150A (en) | 2021-03-31 | 2021-03-31 | Astaxanthin composition, and preparation method, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110350428.9A CN112869150A (en) | 2021-03-31 | 2021-03-31 | Astaxanthin composition, and preparation method, preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112869150A true CN112869150A (en) | 2021-06-01 |
Family
ID=76040344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110350428.9A Pending CN112869150A (en) | 2021-03-31 | 2021-03-31 | Astaxanthin composition, and preparation method, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112869150A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793186A (en) * | 2012-09-04 | 2012-11-28 | 郭威 | Collagen peptide nutritional supplement containing astaxanthin and processing method of same |
| CN111955745A (en) * | 2020-07-24 | 2020-11-20 | 广州长生康生物科技有限公司 | Production process of elastic collagen peptide powder |
| CN111972584A (en) * | 2020-07-13 | 2020-11-24 | 荣成市森维迪生物科技有限公司 | Astaxanthin-containing anti-aging solid beverage |
| CN112245381A (en) * | 2020-11-12 | 2021-01-22 | 珂蓝(重庆)化妆品有限公司 | Skin care product capable of resisting oxidation and improving skin defense capacity |
-
2021
- 2021-03-31 CN CN202110350428.9A patent/CN112869150A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793186A (en) * | 2012-09-04 | 2012-11-28 | 郭威 | Collagen peptide nutritional supplement containing astaxanthin and processing method of same |
| CN111972584A (en) * | 2020-07-13 | 2020-11-24 | 荣成市森维迪生物科技有限公司 | Astaxanthin-containing anti-aging solid beverage |
| CN111955745A (en) * | 2020-07-24 | 2020-11-20 | 广州长生康生物科技有限公司 | Production process of elastic collagen peptide powder |
| CN112245381A (en) * | 2020-11-12 | 2021-01-22 | 珂蓝(重庆)化妆品有限公司 | Skin care product capable of resisting oxidation and improving skin defense capacity |
Non-Patent Citations (3)
| Title |
|---|
| 包卫洋，等: "《海洋生物活性肽的研究与产业化》", 31 December 2020, 海洋出版社 * |
| 周庆新，等: "虾青素的来源、生物功效及吸收代谢研究进展", 《食品研究与开发》 * |
| 赵黎博，等: "化妆品中虾青素相关专利技术综述", 《科技风》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8709511B2 (en) | External preparation composition for skin comprising ginseng flower or ginseng seed extracts | |
| CA2346384C (en) | Method for prevention and/or cosmetic treatment of skin striae and use in dermatology | |
| US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
| FR2880802A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT | |
| CN111000748A (en) | Polypeptide repairing cream and preparation method thereof | |
| MXPA01006891A (en) | Soy depigmenting and skin care compositions. | |
| FR2984742A1 (en) | USE OF STEVIOL, A GLYCOSIDE DERIVATIVE OF STEVIOL, OR ANY OF THEIR ISOMERS, FOR PREVENTING, REDUCING AND / OR TREATING AN ALTERATION OF SKIN PAINT. | |
| KR20090129928A (en) | Composition for applying to skin externally containing extract from flower of ginseng | |
| FR2892302A1 (en) | Herbal agent as substitute for lanolin, obtained by hemi-synthesis of mixture of e.g. (un)saturated fatty acids and a compound comprising hydroxyl groups like glycerol, useful e.g. as soaps and antiperspirant e.g. skin and hair care | |
| Murphy et al. | Clinical studies of the safety and efficacy of macroalgae extracts in cosmeceuticals | |
| US20180353413A9 (en) | Skin compositions containing hydrocortisone | |
| Goodman et al. | Photoaging and cosmeceutical solutions in sun‐overexposed countries: The experience of Australia and Brazil | |
| JP2005027589A (en) | Internal composition for skin care | |
| FR2813018A1 (en) | COSMETIC COMPOSITIONS CONTAINING AT LEAST ONE COMPOUND STIMULATING LAMININ NEOSYNTHESIS, AND/OR INTEGRINE ALPHA-2 BETA-1 AND/OR COLLAGEN IV OF THE DERMO-EPIDERMAL JUNCTION | |
| KR100371028B1 (en) | Cosmetic composition containing Salvia militiorrhira Bge. extracts and polyethoxylated retinamide | |
| CN112869150A (en) | Astaxanthin composition, and preparation method, preparation and application thereof | |
| EP3270942B1 (en) | Use of hylocereus undatus fruit extract as fluorescent colorant of skin | |
| Kyi | A Split-face Double-blind Randomized Placebo-controlled Trial of the Efficacy of Kakadu Plum Extract for Reduction of Periorbital Wrinkles | |
| KR102715235B1 (en) | Cellulite reducing cosmetic composition | |
| Jeyakodi et al. | Efficacy and Safety of a Proprietary Punica Granatum Extract in a Randomized, Placebo-Controlled Clinical Study in Healthy Volunteers | |
| TWI593418B (en) | Use of starfish extract for manufacture of composition for reducing ultraviolet spots, production of porphyrin and sebum production in the skin | |
| Langar | Jessner’s and Resorcinol Peels | |
| Rianto et al. | The Role of Hydrolyzed Oral Collagen Supplementation on Premature Aging in Women Aged 30-60 Years | |
| TWM642748U (en) | Collagen formulation powder packaging structure | |
| WO2024028834A1 (en) | Reduction of signs of skin aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210601 |